Europe Market for Liquid Embolics 2017 - MedCore is a new market research publication announced by Reportstack.
General Report Contents• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Growth in unit sales will be very stable over the forecast period. “A Randomized Trial of Unruptured Brain Arteriovenous Malformations” (ARUBA) compared interventional and conservative treatment of arteriovenous malformations in the brain and found that conservative management with medication was more effective than embolization. However, some experts have expressed concerns regarding the clinical conclusions of the study due to relatively short follow-up and difficulties with patient recruitment. Therefore even due the market limiter imposed by the trial results, unit sales have continues to grow steadily in line with procedural growth. Approximately two to three units of liquid embolics are needed on average for procedures.
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Growth in unit sales will be very stable over the forecast period. “A Randomized Trial of Unruptured Brain Arteriovenous Malformations” (ARUBA) compared interventional and conservative treatment of arteriovenous malformations in the brain and found that conservative management with medication was more effective than embolization. However, some experts have expressed concerns regarding the clinical conclusions of the study due to relatively short follow-up and difficulties with patient recruitment. Therefore even due the market limiter imposed by the trial results, unit sales have continues to grow steadily in line with procedural growth. Approximately two to three units of liquid embolics are needed on average for procedures.
Complete report available @ Europe Market for Liquid Embolics 2017 - MedCore
The ASP is also expected to remain stable as there is only one competitor in the market. There may be others that enter the market over the forecast period but this technology has held a monopoly on this market for many years now.
Scope
2013-2023
2013-2023
Companies Mentioned
Medtronic Stryker Codman & Shurtleff, Inc. St. Jude Medical Nevro Carl Zeiss Boston Scientific LivaNova Terumo MicroVention Penumbra Inc. Leica Integra LifeSciences BrainLab Balt Magstim Phenox MagVenture Elekta Moëller Wedel Misonix Sophysa Aesculap MAG & More Neurosoft Acandis Soring Brainsway Nexstim Others include: ANT, Asahi Intecc, Axonics, Blockade, Dispomedica, Enteromedics, Flowonix, Inomed, Intrapace, Kaneka Medical Products, MHT, Micrus Endovascular, MRC, Navimetric, Neuravi, Neuronetics, Neuropace, NextGen Medicla System, Nuvectra, Scientia Vascular, Spiegelberg, Stimwave, Tokai Medical Product, Tricumed, Vascular Solutions, etc.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
No comments:
Post a Comment